The prognostic features most commonly used in adjuvant treatment decision for node-negative patients include patient age, menopausal status, tumor size, tumor grade, Ki-67 score, HER2 status, and strength of estrogen receptor (ER)/progesterone receptor (PR) expression. Here, MKI67 is linked to neoplasm.